LDN 193189 dihydrochloride
Potent and selective ALK2 and ALK3 inhibitor (IC50 values are 5 and 30 nM, respectively); inhibits BMP4-mediated Smad1/5/8 activation. Exhibits >200-fold selectivity for BMP signaling over TGF-β signaling. Also exhibits selectivity over AMPK, PDGFR and MAPK signaling. Promotes neural induction of hPSCs in combination with SB 431542 (Cat.No. 1614). Also induces differentiation of hPSCs into nociceptive sensory neurons in combination with SB 431542 (Cat.No. 1614), SU 5402 (Cat.No.3300), CHIR 99021 (Cat.No. 4423) and DAPT (Cat.No. 2634).
Sold for research purposes under exclusive agreement from The Brigham and Women's Hospital Inc. US patents 8,507,501 and 9,045,484
iPS differentiation with LDN 193189
Image shows IBJ6 human fibroblast induced pluripotent stem cells which have been differentiated into motor neurons. This was performed using a combination of LDN 193189 (100 nM) and SB 431542 (Cat. No. 1614) followed by Retinoic acid (Cat. No. 0695) and Purmorphamine (Cat. No. 4551) culture on Laminin for 18 days. Commitment to the motor neuron fate was accessed using the motor neuron marker anti-Human Islet-1 (red, R&D Systems®, Cat. No. AF1837) and the general neuronal marker, beta III tubulin (green, R&D Systems®, Cat. No. MAB1195). For visualization, the neurons were stained using Northernlights™ 557-conjugated Donkey anti-Goat Secondary Antibody (R&D Systems®, Cat. No. NL001) and Northernlights™ 493-conjugated Donkey anti-Mouse Secondary Antibody (R&D Systems®, Cat. No. NL009).
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 479.4. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.09 mL||10.43 mL||20.86 mL|
|5 mM||0.42 mL||2.09 mL||4.17 mL|
|10 mM||0.21 mL||1.04 mL||2.09 mL|
|50 mM||0.04 mL||0.21 mL||0.42 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Yu et al (2008) BMP type I receptor inhibition reduces heterotopic ossification. Nat.Med. 14 1363 PMID: 19029982
Chambers et al (2012) Combined small-molecule inhibition accelerates developmental timing and converts human pluripotent stem cells into nociceptors. Nat.Biotechnol. 30 715 PMID: 22750882
Cuny et al (2008) Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. Bioorg.Med.Chem.Lett. 18 4388 PMID: 18621530
Li et al (2013) Chemical approaches to stem cell biology and therapeutics. Cell Stem Cell 13 270 PMID: 24012368
If you know of a relevant reference for LDN 193189 dihydrochloride, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: LDN193189 dihydrochloride BMP signaling ALK2 ALK3 activin bone morphogenetic proteins stem cells neural differentiation neurons BMP and Other Activin Receptors
Citations for LDN 193189 dihydrochloride
Citations are publications that use Tocris products.
Currently there are no citations for LDN 193189 dihydrochloride. Do you know of a great paper that uses LDN 193189 dihydrochloride from Tocris? If so please let us know.